Trials / Completed
CompletedNCT00289900
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,340 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A coadministered with simvastatin) will be superior to atorvastatin on decreasing the low denisity lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio for the following dose comparisons: 2g/20 mg MK-0524B versus 10 mg atorvastatin, 2g/40 mg MK-0524B versus 20 mg atorvastatin, 2g/40 mg MK-0524B versus 40 mg atorvastatin, and 2g/40 mg MK-0524B versus 80 mg atorvastatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-0524A | |
| DRUG | Atorvastatin | |
| DRUG | Simvastatin |
Timeline
- Start date
- 2006-01-24
- Primary completion
- 2010-08-06
- Completion
- 2010-08-06
- First posted
- 2006-02-10
- Last updated
- 2018-08-31
- Results posted
- 2016-01-26
Source: ClinicalTrials.gov record NCT00289900. Inclusion in this directory is not an endorsement.